beta-endorphin and Trigeminal-Neuralgia

To investigate the expression levels of calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin in the cerebrospinal fluid (CSF) and peripheral blood of patients with primary trigeminal neuralgia (TN).. We included 20 patients with primary TN who underwent percutaneous radiofrequency thermocoagulation and collected four types of samples from all of them: sample A: CSF samples; sample B: peripheral blood samples; sample C: peripheral blood samples collected one day before the operation; sample D: peripheral blood samples withdrawn one day after the operation. Another 20 CSF samples of patients with nervous system disease or gynecological disease were collected as a control (sample E). Samples A and B were obtained at the same time. We also evaluated the expression of CGRP, SP, β-endorphin, and VIP by visual analog scale (VAS) scores one day before and one day after the operation. In addition, heart rate (HR) at baseline and at the time of sample collection, mean arterial pressure (MAP), and all side effects of the procedure were recorded.. Significance were found concerning about CGRP, SP, β-endorphin, and VIP in TN patients and the controls (P<0.001). The expression of CGRP, SP, and VIP in sample A was higher than that in sample E. However, the β-endorphin level in sample A was lower than that in sample E. There was a positive correlation between sample A and B regarding the expression of CGRP, SP, β-endorphin, and VIP (P<0. 01). There was no relationship between the time of disease onset and the expression of CGRP, SP, β-endorphin, and VIP in sample A and sample B (P>0.05). No difference was detected between the neuropeptides levels in samples B and C (P>0.05). Notably, VAS in sample D was significantly lower than that in sample C (P<0.01). Finally, there was no difference between the intraoperative HR and MAP values in the studied samples.. In primary TN patients, the blood levels of CGRP, SP, β-endorphin, and VIP were associated with those in CSF samples. There was a significant difference between the levels of the four neuropeptides in CSF and control samples. Our results also indicated that the levels of neuropeptides in blood samples can be tested for those in CSF. The disease onset and duration exerted insignificant effects on the production and release of CGRP, SP, β-endorphin, and VIP.

Topics: Adult; Aged; beta-Endorphin; Biomarkers; Calcitonin Gene-Related Peptide; Electrocoagulation; Female; Humans; Male; Middle Aged; Neuropeptides; Substance P; Trigeminal Neuralgia; Vasoactive Intestinal Peptide

To determine the level and the role of beta-endorphin in hypothalamus of rat with trigeminal neuralgia.. The animal model of primary trigeminal neuralgia in rat was established, the contents of beta-endorphin were measured by radioimmunoassay techniques.. The beta-endorphin of hypothalamus in experimental group was significantly lower than other groups (P < 0.01).. Beta-endorphin may play important roles in primary trigeminal neuralgia.

Topics: Animals; beta-Endorphin; Hypothalamus; Rats; Rats, Wistar; Trigeminal Neuralgia

The authors describe a new method of the treatment of patients with trigeminal neuralgias using electroconvulsive therapy. The method is based on the increase of beta-endorphin concentration as a result of electroconvulsive treatment. The treatment of 12 patients in accordance with the suggested method provided beneficial results and significant enhancement of the efficacy of therapy as compared to patients undergoing conventional treatment.

Topics: Adult; beta-Endorphin; Chronic Disease; Electroconvulsive Therapy; Female; Humans; Immunoglobulins; Leukocyte Count; Male; Middle Aged; T-Lymphocytes; Trigeminal Neuralgia

The authors provide the results of an analysis of the interrelation between the immunologic and biochemical parameters in 6 groups of patients suffering from facial pains or headaches (a total of 153 patients). Significant correlations were revealed in the patients' groups with trigeminal neuralgia and periodic migrainous Horton's neuralgia. The main attention was concentrated on the following parameters: IgA in the serum, secretory IgA in the patients' saliva, % CD4 of lymphocytes and histamine concentration in the peripheral blood, concentration of beta-endorphin in the plasma, catecholamine content in the urine.

Topics: beta-Endorphin; Catecholamines; Humans; Immunoglobulin A; Immunoglobulin A, Secretory; Leukocyte Count; Saliva; T-Lymphocytes; Temporomandibular Joint Disorders; Trigeminal Neuralgia; Vascular Headaches

Somatosensory evoked potentials, biochemical, immunological, pharmacokinetic and psychological research methods were used to examine 308 patients suffering from neuralgia of the trigeminal and glossopharyngeal nerves, neuropathy of the trigeminal nerve, neuralgias of the face and painful dysfunction of the temporomandibular articulation. New mechanisms of the pathogenesis of the diseases indicated were revealed. That made it possible to improve and devise new treatment methods.

Topics: beta-Endorphin; Combined Modality Therapy; Facial Neuralgia; Glossopharyngeal Nerve; Head; Humans; Neuralgia; Nociceptors; Prostaglandins E; Temporomandibular Joint Dysfunction Syndrome; Trigeminal Neuralgia

Blood plasma beta-endorphin concentrations were measured in 87 patients with various facial and head pain syndromes: trigeminal neuralgia or neuropathy Horner syndrome and migraine, facial autonomic pains. beta-endorphin concentrations were measured before and after treatment. In the groups under investigation, the neuropeptide showed opposite changes in plasma levels after the therapy depending on the type of the syndrome.

Topics: Adult; beta-Endorphin; Cluster Headache; Female; Humans; Male; Middle Aged; Migraine Disorders; Trigeminal Neuralgia; Vascular Headaches

Topics: Adult; beta-Endorphin; beta-Lipotropin; Endorphins; Female; Humans; Male; Middle Aged; Trigeminal Neuralgia

The beta-endorphin content in cerebrospinal fluid (CSF) was evaluated in 10 patients with idiopathic trigeminal neuralgia during medical treatment (with or without carbamazepine) and after selective thermocoagulation of the Gasserian ganglion. These values were compared with those obtained in a control group of seven patients without pain problems. No statistically significant difference was found between patients suffering from trigeminal neuralgia and those without pain. Furthermore, neither pharmacological treatment nor surgery changed CSF endorphin values. It is concluded that there is no pathogenetic relationship between trigeminal neuralgia and endorphins.

Topics: Adult; beta-Endorphin; Carbamazepine; Endorphins; Female; Humans; Male; Middle Aged; Palliative Care; Trigeminal Neuralgia